Trial reportAnnals of clinical and translational neurology2026
Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability.
Trial report in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Telemedical communication patterns in myasthenia gravis in a remote monitoring study.Neurological research and practice · 2026Article
- Role of complement and complement-targeted therapeutics in neurological diseases.Nature reviews. Neurology · 2026Review
- Patient Communication Outside of Visits: Implications for Remote Monitoring and Digital Care Models in Myasthenia Gravis.Muscle & nerve · 2026Article
- Digital assessment in myasthenia gravis: evidence, validation, and a proposed framework for autoimmune heterogeneity, remote monitoring, and clinical endpoints.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMyasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life-threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients. This study evaluated whether frequently assessed clinical outcomes via MyaLink can capture symptom variability between clinical visits.
methodsIn this randomized, controlled, 12-week study, 45 MG patients received either standard care (control, N = 15) or standard care with additional telemedical treatment (intervention, N = 30) including assessment of patient-reported outcome measures, sensor-based data, and patient-physician messaging via a mobile application. Physicians performed telemedical check-ups (TCUs) via a web-based platform, adjusting treatment as needed.
resultsIn the intervention group, variability in clinical scores and sensor-derived data was observed, particularly among those who experienced MG-related hospitalizations or exacerbations (H&E subgroup). This subgroup showed larger MG-ADL score fluctuations (mean range: 5.8 vs. 2.6 points), sent more messages, had more steroid dose adjustments (40% vs. 0%), and more frequent TCU interventions (93.3% vs. 60%) than the Non-H&E subgroup.
interpretationTelemedical platforms in MG might detect early signs of worsening. High-risk patients (H&E subgroup) require increased medical support, which can be effectively addressed through MyaLink.
trial registrationThe study was registered under the German clinical trial registry (DRKS00029907).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.